Alexion Pharmaceuticals, Inc. - All News Releases
Alexion to Present at Investor Conferences
Posted: June 3, 2014, 2:00 pm
New Data Presented at the ERA-EDTA Congress Demonstrate Efficacy of Soliris® (eculizumab) in Broad Range of Patients with atypical Hemolytic Uremic Syndrome (aHUS)
Posted: June 2, 2014, 11:15 am
Alexion Initiates Voluntary Nationwide Recall of Certain Lots of Soliris® (eculizumab) Concentrated Solution for Intravenous Infusion Due to the Presence of Visible Particulate Matter in a Single Lot
Posted: June 2, 2014, 10:59 am
New Data Detailing the Devastating Nature of Hypophosphatasia (HPP) and Treatment Effect of Asfotase Alfa in Infants, Young Children and Juveniles with HPP Presented at the Pediatric Academic Societies Meeting
Posted: May 6, 2014, 12:02 am
FDA Approves Conversion of Soliris® (eculizumab) Accelerated Approval in aHUS to Regular Approval for the Treatment of Patients with aHUS
Posted: May 5, 2014, 10:30 am
Alexion to Present at Investor Conferences
Posted: May 1, 2014, 2:00 pm
Alexion Reports First Quarter 2014 Results
Posted: April 24, 2014, 10:30 am
Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica (NMO) and Refractory Generalized Myasthenia Gravis (MG)
Posted: April 24, 2014, 10:15 am
European Commission Grants Orphan Drug Designation to Soliris® (Eculizumab) for the Prevention of Graft Rejection Following Solid Organ Transplantation
Posted: April 23, 2014, 10:30 am
Alexion Announces the Appointment of John T. Mollen to Its Board of Directors
Posted: April 17, 2014, 8:15 pm